EDWARDS LIFESCIENCES ($EW) posted quarterly earnings results on Wednesday, April 23rd. The company reported earnings of $0.64 per share, beating estimates of $0.61 by $0.03. The company also reported revenue of $1,412,700,000, missing estimates of $1,443,195,294 by $-30,495,294.
You can see Quiver Quantitative's $EW stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EDWARDS LIFESCIENCES Insider Trading Activity
EDWARDS LIFESCIENCES insiders have traded $EW stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $EW stock by insiders over the last 6 months:
- SCOTT B. ULLEM (CVP, Chief Financial Officer) has made 0 purchases and 5 sales selling 45,000 shares for an estimated $3,252,271.
- DONALD E JR BOBO (CVP,Strategy/Corp Development) has made 0 purchases and 7 sales selling 40,500 shares for an estimated $2,831,512.
- LARRY L WOOD (Global President TAVR & Surg) sold 25,000 shares for an estimated $1,647,862
- STEVEN R LORANGER sold 5,739 shares for an estimated $438,575
- HEISZ LESLIE STONE sold 5,739 shares for an estimated $435,370
- BERNARD J ZOVIGHIAN (CEO) sold 6,164 shares for an estimated $428,447
- DANIEL J. LIPPIS (CVP, JAPAC) has made 0 purchases and 5 sales selling 4,200 shares for an estimated $306,722.
- DAVEEN CHOPRA (CVP, TMTT) sold 1,750 shares for an estimated $128,222
- WAYNE MARKOWITZ (GM & SVP, Surgical) sold 583 shares for an estimated $42,716
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EDWARDS LIFESCIENCES Hedge Fund Activity
We have seen 467 institutional investors add shares of EDWARDS LIFESCIENCES stock to their portfolio, and 637 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JENNISON ASSOCIATES LLC added 7,509,650 shares (+inf%) to their portfolio in Q4 2024, for an estimated $555,939,389
- CITADEL ADVISORS LLC added 7,426,571 shares (+372.9%) to their portfolio in Q4 2024, for an estimated $549,789,051
- VANGUARD GROUP INC added 6,537,494 shares (+10.4%) to their portfolio in Q4 2024, for an estimated $483,970,680
- JPMORGAN CHASE & CO added 6,385,779 shares (+75.4%) to their portfolio in Q4 2024, for an estimated $472,739,219
- SANDS CAPITAL MANAGEMENT, LLC removed 5,320,024 shares (-99.7%) from their portfolio in Q4 2024, for an estimated $393,841,376
- ALLIANCEBERNSTEIN L.P. removed 4,944,582 shares (-70.8%) from their portfolio in Q4 2024, for an estimated $366,047,405
- CIBC PRIVATE WEALTH GROUP LLC removed 2,302,841 shares (-91.1%) from their portfolio in Q4 2024, for an estimated $170,479,319
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EDWARDS LIFESCIENCES Government Contracts
We have seen $27,051,057 of award payments to $EW over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- EXPRESS REPORT: 2ND QTR FY25 TAVR HEART VALVES WITH CONSIGNMENT DELIVERY: $261,500
- BILL PAY TRANSACTIONS: $238,000
- EXPRESS REPORT: IMPLANT BILL ONLY: $236,500
- SURGICAL IMPLANTS - TRANSCATHETER HEART VALVE: $204,000
- EDWARDS LIFESCIENCES HEART VALVES: $204,000
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
EDWARDS LIFESCIENCES Congressional Stock Trading
Members of Congress have traded $EW stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $EW stock by members of Congress over the last 6 months:
- REPRESENTATIVE BRUCE WESTERMAN purchased up to $15,000 on 03/03.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
EDWARDS LIFESCIENCES Analyst Ratings
Wall Street analysts have issued reports on $EW in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 12/05/2024
- Oppenheimer issued a "Outperform" rating on 12/05/2024
- Goldman Sachs issued a "Buy" rating on 10/30/2024
- Citigroup issued a "Buy" rating on 10/28/2024
To track analyst ratings and price targets for EDWARDS LIFESCIENCES, check out Quiver Quantitative's $EW forecast page.
EDWARDS LIFESCIENCES Price Targets
Multiple analysts have issued price targets for $EW recently. We have seen 7 analysts offer price targets for $EW in the last 6 months, with a median target of $78.0.
Here are some recent targets:
- Rick Wise from Stifel Nicolaus set a target price of $90.0 on 01/29/2025
- Lee Hambright from Bernstein set a target price of $74.0 on 01/08/2025
- Richard Newitter from Truist Financial set a target price of $78.0 on 12/05/2024
- William Plovanic from Canaccord Genuity set a target price of $68.0 on 12/05/2024
- David Roman from Goldman Sachs set a target price of $80.0 on 10/30/2024
- Travis Steed from Bank of America Securities set a target price of $75.0 on 10/30/2024
- Joanne Wuensch from Citigroup set a target price of $81.0 on 10/28/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
